Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Molecular Biomarker Testing and Targeted Therapy Patterns in Patients with Acute Myelogenous Leukemia (AML) in Community Health Systems in the United States: A Real-World Data Analysis

Francesca Coutinho, Zartash Gul, Anna B. Berry, Michael A. Thompson, Christopher Allen Willner, II, Sowjanya Vuyyala, Haley McCracken, Katherine Geverd, Jeanna Wallenta Law, Frank M. Wolf, Thomas D. Brown, Philip Kuriakose

Blood (2021) 138 (Supplement 1): 4443.

https://doi.org/10.1182/blood-2021-148634

Published: 2021

Journal Articles

Therapeutic Targeting of the Ubiquitin Conjugating Enzyme UBE2N in Myeloid Malignancies

Blood (2018) 132 (Supplement 1): 4050.

https://doi.org/10.1182/blood-2018-99-115359

Published: 2018

Journal Articles

Low Incidence Of Severe Cgvhd and Late NRM In a Phase II Trial Of Thymoglobulin®, Tacrolimus and Sirolimus For Gvhd Prevention

Zaid Al-Kadhimi, MD, Alireza Eghtedar, MD, Zartash Gul, MD, Wei Chen, PhD, Daryn Smith, Abhinav Deol, MD, Muneer H. Abidi, MD, Lawrence G Lum, MD, DSc, Divaya Bhutani, MD, Lois Ayash, MD, Voravit Ratanatharathorn, MD, Joseph P. Uberti, MD, PhD

Blood (2013) 122 (21): 5471.

https://doi.org/10.1182/blood.V122.21.5471.5471

Published: 2013

Journal Articles

Is Rituximab Needed With High Dose Chemotherapy and Autologous Stem Cell Transplant When Patients With Non-Hodgkin’s Lymphoma Have Been Exposed To It?

Zartash Gul, MD, Stephan Anderson, MD, Stacey Slone, Saurabh Chhabra, MD, Gregory Monohan, MD, Dianna Howard, MD, Amber Lawson, PharmD, John Hayslip, MD

Blood (2013) 122 (21): 5552.

https://doi.org/10.1182/blood.V122.21.5552.5552

Published: 2013

Journal Articles

EBMT Risk Score for Pre Transplant Risk Assessment in Patients with Multiple Myeloma.

Zartash Gul, MD, Hasan Khan, Qaiser Bashir, MD, Nina Shah, MD, Simrit Parmar, M.D., Yvonne T Dinh, Chitra M. Hosing, M.D., Uday R. Popat, M.D., Partow Kebriaei, M.D., Paolo Anderlini, MD, Elizabeth J Shpall, MD, Sergio Giralt, MD, Richard E. Champlin, Muzaffar H. Qazilbash, MD

Blood (2012) 120 (21): 3094.

https://doi.org/10.1182/blood.V120.21.3094.3094

Published: 2012

Journal Articles

High Rates of Severe aGVHD with Tacrolimus and Mycophenolate Mofetil in a Large Cohort of Related and Unrelated Allogeneic Transplant Patients

Zaid Al-Kadhimi, MD, Zartash Gul, MD, Wei Chen, PhD, Daryn Smith, Abhinav Deol, MD, Muneer H. Abidi, MD, Lois Ayash, MD, Lawrence G Lum, MD, DSc, Voravit Ratanatharathorn, MD, Joseph P. Uberti, MD, PhD

Blood (2012) 120 (21): 1951.

https://doi.org/10.1182/blood.V120.21.1951.1951

Published: 2012

Journal Articles

Cardiac Toxicity After High-Dose Melphlan and Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma

Zartash Gul, MD, Qaiser Bashir, MD, Yago Nieto, M.D., Ph.D., Nazeer Sherwani, Simrit Parmar, M.D., Nina Shah, MD, Yvonne T Dinh, Chitra M. Hosing, M.D., Uday R. Popat, M.D., Partow Kebriaei, M.D., Elizabeth J Shpall, MD, Sergio A Giralt, MD, Richard E. Champlin, Muzaffar H. Qazilbash, MD

Blood (2012) 120 (21): 2027.

https://doi.org/10.1182/blood.V120.21.2027.2027

Published: 2012

Journal Articles

A Prospective Phase II Trial: The Combination of Tacrolimus, Sirolimus, and Rabbit Anti-Thymocyte Globulin (Thymoglobulin® Thymo) to Prevent Acute Graft Vs. Host Disease (aGVHD) in Patients Receiving Unrelated Hematopoietic Stem Cell Transplantation (UHSCT)

Zaid Al-Kadhimi, MD, Zartash Gul, MD, Roberto Rodriguez, MD, Wei Chen, PhD, Alice Mitchell, BS, Muneer H. Abidi, MD, Lois Ayash, MD, Abhinav Deol, MD, Lawrence G Lum, MD, DSc, Voravit Ratanatharathorn, MD, Joseph P. Uberti, MD, PhD

Blood (2011) 118 (21): 4551.

https://doi.org/10.1182/blood.V118.21.4551.4551

Published: 2011

Journal Articles

Obesity and the Risk of Non-Hodgkin's Lymphoma – A Meta-Analysis Involving More Than 40,000 Cases

Nishant Tageja, MD, Ivo Ditah, MD, Zartash Gul, MD

Blood (2010) 116 (21): 5089.

https://doi.org/10.1182/blood.V116.21.5089.5089

Published: 2010

Journal Articles

Comparison of Clinical Outcomes and Day 30 Lymphocyte Recovery Between Two aGVHD Prophylaxis Regimens In Matched Unrelated Hematopoietic Stem Cell Transplant (MUD) Patients

Zartash Gul, MD, Mustafa Abdul-Hussein, MD, Ivo Ditah, MD, Joseph P. Uberti, MD, PhD, Muneer H. Abidi, MD, Lois Ayash, MD, Lawrence G. Lum, MD, DSC, Voravit Ratanatharathorn, MD, Zaid Al-Kadhimi, MD

Blood (2010) 116 (21): 2340.

https://doi.org/10.1182/blood.V116.21.2340.2340

Published: 2010

Journal Articles

A Phase I Study of Bortezomib During Maintenance Phase After High-Dose Melphalan and Autologous Stem Cell Transplantation In Patients with Multiple Myeloma

Muneer H. Abidi, MD, Zartash Gul, MD, Lawrence G. Lum, MD, DSC, Judith Abrams, Simon Cronin, Pharm, D, Marie Ventimiglia, Abhinav Deol, MBBS, MD, Lois Ayash, Zaid Al-Kadhimi, Voravit Ratanatharathorn, MD, Joseph P. Uberti, MD, PhD

Blood (2010) 116 (21): 2387.

https://doi.org/10.1182/blood.V116.21.2387.2387

Published: 2010

Journal Articles

MD.

Zartash Gul, MD, Naomi Galili, PhD, Nishant Tageja, MD, Azra Raza, MD

Blood (2009) 114 (22): 4863.

https://doi.org/10.1182/blood.V114.22.4863.4863

Published: 2009

Journal Articles

The Combination of Tacrolimus (T), Sirolimus (S), and Rabbit Anti-Thymocyte Globulin (Thymoglobulin Thymo) to Prevent Acute Graft-Vs-Host Disease (aGVHD) in Patients (pts) Receiving Unrelated Hematopoietic Stem Cell Transplantation (UHSCT).

Zaid S Al-Kadhimi, M.D, Zartash Gul, MD, Lawrence G. Lum, MD, DSC, Lois Ayash, MD, Muneer H. Abidi, MD, Wei Chen, PhD, Alice Mitchell, BS, Voravit Ratanatharathorn, M.D, Joseph Uberti, M.D., Ph.D

Blood (2009) 114 (22): 2239.

https://doi.org/10.1182/blood.V114.22.2239.2239

Published: 2009

NARROW

Molecular Biomarker Testing and Targeted Therapy Patterns in Patients with Acute Myelogenous Leukemia (AML) in Community Health Systems in the United States: A Real-World Data Analysis

Therapeutic Targeting of the Ubiquitin Conjugating Enzyme UBE2N in Myeloid Malignancies

Low Incidence Of Severe Cgvhd and Late NRM In a Phase II Trial Of Thymoglobulin®, Tacrolimus and Sirolimus For Gvhd Prevention

Is Rituximab Needed With High Dose Chemotherapy and Autologous Stem Cell Transplant When Patients With Non-Hodgkin’s Lymphoma Have Been Exposed To It?

EBMT Risk Score for Pre Transplant Risk Assessment in Patients with Multiple Myeloma.

High Rates of Severe aGVHD with Tacrolimus and Mycophenolate Mofetil in a Large Cohort of Related and Unrelated Allogeneic Transplant Patients

Cardiac Toxicity After High-Dose Melphlan and Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma

A Prospective Phase II Trial: The Combination of Tacrolimus, Sirolimus, and Rabbit Anti-Thymocyte Globulin (Thymoglobulin® Thymo) to Prevent Acute Graft Vs. Host Disease (aGVHD) in Patients Receiving Unrelated Hematopoietic Stem Cell Transplantation (UHSCT)

Obesity and the Risk of Non-Hodgkin's Lymphoma – A Meta-Analysis Involving More Than 40,000 Cases

Comparison of Clinical Outcomes and Day 30 Lymphocyte Recovery Between Two aGVHD Prophylaxis Regimens In Matched Unrelated Hematopoietic Stem Cell Transplant (MUD) Patients

A Phase I Study of Bortezomib During Maintenance Phase After High-Dose Melphalan and Autologous Stem Cell Transplantation In Patients with Multiple Myeloma

MD.

The Combination of Tacrolimus (T), Sirolimus (S), and Rabbit Anti-Thymocyte Globulin (Thymoglobulin Thymo) to Prevent Acute Graft-Vs-Host Disease (aGVHD) in Patients (pts) Receiving Unrelated Hematopoietic Stem Cell Transplantation (UHSCT).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only